Phone therapy boosts inhaler use in anxious asthma patients
NCT ID NCT06732141
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether weekly phone calls with education, relaxation techniques, and motivational interviewing can help adults with asthma who are anxious about using their inhalers. 216 participants will be split into two groups: one gets the extra phone support, the other gets standard care. The goal is to see if the calls improve inhaler use, reduce anxiety, and lead to better asthma control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 216 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age Requirement: Participants must be aged 18 to 80 years, ensuring they are adults capable of making decisions and responding effectively to interventions. 2. Diagnosed Asthma: 1. Diagnosis must meet the criteria of the Global Initiative for Asthma (GINA) or the American Academy of Asthma guidelines, with at least one confirmed diagnosis by a specialist in the past six months. 2. Asthma severity must range from mild to moderate persistent, in the chronic management phase, excluding patients in acute exacerbation phases for clearer evaluation of adherence and intervention effects. 3. ICS Treatment History: 1. Participants must have been on inhaled corticosteroid (ICS) therapy for at least six months, ensuring sufficient treatment history for adherence and effect evaluation. 2. No major changes to asthma control medication regimen in the past six months, ensuring adherence and intervention outcomes are not confounded by treatment changes. 4. Poor Medication Adherence: Identified using the Medication Adherence Report Scale (MARS-10), with an average score \<4.5, indicating suboptimal adherence. 5. Presence of Anxiety Symptoms: 1. Confirmed through the Hamilton Anxiety Rating Scale (HAMA), with a score ≥14, indicating clinically significant anxiety. 2. Anxiety symptoms must be related to asthma treatment, particularly concerns about ICS side effects or long-term use, ensuring the psychological intervention targets relevant issues. 6. Ability to Communicate by Phone: Participants must have stable access to a phone and be willing to engage in telephone-based psychological interventions. 7. Stable Health Condition: Asthma status must be stable, with no acute exacerbations or significant changes in the past month. Exclusion Criteria: 1. Severe Psychiatric or Cognitive Disorders: 1. Diagnosis of major psychiatric disorders, such as major depressive disorder, bipolar disorder, schizophrenia, or other severe mental illnesses within the past six months, based on DSM-5 criteria. 2. Presence of cognitive impairments or neurological conditions, such as dementia or post-stroke complications, that may affect comprehension or adherence to the intervention. 3. Current psychiatric treatment involving antipsychotics, antidepressants, or sedatives that could interfere with the intervention's outcomes. 2. Substance Abuse or Dependence: History of alcohol or drug abuse within the past six months, including but not limited to opioids, benzodiazepines, or illicit substances. 3. Severe Comorbidities: 1. Uncontrolled respiratory or cardiovascular conditions, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, interstitial lung disease, heart failure, or uncontrolled hypertension, that could significantly impact asthma control and overall health. 2. Chronic diseases requiring long-term systemic corticosteroid therapy, such as rheumatic or autoimmune diseases, that may interfere with ICS treatment and study outcomes. 4. Pregnancy or Lactation: Pregnant or breastfeeding women are excluded due to the unclear risks of ICS treatment and anxiety management interventions in these populations. 5. Allergic Bronchopulmonary Aspergillosis (ABPA) or Related Conditions: Diagnosed ABPA or other respiratory diseases with mechanisms distinct from asthma, which could confound the assessment of ICS treatment effects. 6. Participation in Other Interventional Clinical Trials: Participation in another interventional clinical trial within the past three months, particularly those involving respiratory diseases or medication adherence management, to avoid confounding effects on outcomes. 7. Incompatibility with Telephone-Based Interventions: Inability to reliably receive or engage in telephone-based psychological interventions due to hearing impairments, communication barriers, or other reasons. 8. Adverse Reactions to Psychological Interventions: Documented refusal of or adverse reactions to psychological interventions, such as phone-based relaxation or motivational interviewing, that could affect the feasibility and effectiveness of the study. 9. History of Major Surgery or Hospitalization: History of major surgery or hospitalization (unrelated to asthma) within the past six months that might impact current health status and introduce bias into the study outcomes.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
11 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Anhui Chest Hospital
RECRUITINGHefei, China
-
Haishu District People's Hospital
NOT_YET_RECRUITINGNingbo, China
-
Jingzhou Central Hospital
RECRUITINGJingzhou, China
-
Ningbo Medical Center Lihuili Hospital
RECRUITINGNingbo, China
-
Ninghai County First Hospital
RECRUITINGNinghai, China
-
Qianhu Hospital
RECRUITINGNingbo, China
-
Second Affiliated Hospital of Harbin Medical University
RECRUITINGHarbin, China
-
Taizhou Central Hospital
NOT_YET_RECRUITINGTaizhou, China
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
-
The First Affiliated Hospital of Ningbo University
RECRUITINGNingbo, China
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple breath test cut asthma Flare-Ups?
- Breathing tests face off: can extra lung measurements improve asthma diagnosis?
- The carbon label on your inhaler: can it sway a Doctor's choice?
- Six biologics put to the test in Real-World asthma and COPD care
- Can a digital program help teens with chronic illnesses move to adult care?
- Why do some kids catch every cold? a 1,200-Child study hunts for immune clues